Marksans Pharma has posted strong growth in top line and bottom line during the quarter ended June 2014 and its consolidated net profit went up by 35.6 per cent to Rs.25.47 crore from Rs.18.78 crore in the similar quarter of last year. Its consolidated net sales also improved by 43.5 per cent to Rs.202.40 crore from Rs.141.03 crore. The earnings per share touched to Rs.0.67 as against Rs.0.50 in the last period.
EBDITA improved sharply to Rs.42.80 from Rs.26.46 crore, a growth of 61.8 per cent. Its interest cost increased slightly to Rs.3.54 crore from Rs.3.26 crore. With strong growth in profits, Marksans Pharma scrip touched to its yearly high at Rs.36.40 in the morning session on BSE today.
Its formulation business in Europe improved smartly by 40 per cent to Rs.132 crore from Rs.94.50 crore and the same in US & North America improved by 67.8 per cent to Rs.35.40 crore from Rs.21.1 crore. It achieved revenue of Rs.18.9 crore in Australia and New Zealand from formulation business.
For the full year ended March 2014, Marksans' net sales improved to Rs.634 crore and it earned a net profit of Rs.71.91 crore. As against the equity capital of Rs.38.53 crore its reserves stood at Rs.90.15 crore.